• 1
  • 1
  • 收藏

Salarius Plans To Enter $15B Protein Degradation Space With DeuteRx Deal

Benzinga2022-01-13

Salarius Pharmaceuticals Inc has agreed to acquire an oral, small molecule targeted protein degradation portfolio against cancer from DeuteRx LLC.

  • The acquisition includes a lead drug candidate that Salarius has renamed SP-3164 (formerly DRX-164).
  • "This strategic acquisition is a transformative event for Salarius that significantly expands our development pipeline while building upon the momentum of our lead clinical-stage candidate, seclidemstat," stated David Arthur, CEO of Salarius.
  • SP-3164 is a next-generation cereblon-binding molecular glue. Molecular glues are small molecules that commandeer the body's normal protein-degradation processes and induce selective elimination of cancer-causing proteins.
  • Salarius plans to begin the first clinical trial in 2023.
  • As part of the agreement, Salarius and DeuteRx will collaborate to complete SP-3164 development activities and collaborate on the R&D of future products.
  • Under the agreement terms, DeuteRx will receive an upfront payment consisting of $1.5 million in cash and 1 million shares of restricted stock.
  • SP-3164, DeuteRx is also entitled to receive up to $188 in milestone payments.
  • Additionally, DeuteRx is eligible to receive milestone payments of up to $84 million for each of two future products.
  • Price Action: SLRX shares traded 1.52% higher at $0.50 premarket on the last check Thursday.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

举报

评论1

  • rachellll
    ·2022-01-13
    Wqqq
    回复
    举报
    收起
 
 
 
 

热议股票

 
 
 
 
 

7x24